Inventor · disambiguated record
Laszlo Urogdi
Also filed as: UEROEGDI LASZLO · UEROGDI LASZLO · UROGDI LASZLO
18 granted patents·3 pending applications·232 citations·filing 1975–2010
95Inventor score
Files withCYTRX CORP9BIOREX KUTATO FEJLESZTOE KFT3RICHTER GEDEON VEGYESZET3BERGMANN JOHN E1BIOREX KUTATO ES FEJLESZOERT1
Top patents by PatentIndex Score
21 records- 0193US7691849B2Carboxamidine derivatives and their use in the treatment of vascular diseasesCYTRX CORP·Filed 2007·Granted Apr 6, 2010·14 cites·27 claims
- 0291US7786139B2PDE10 inhibitors and related compositions and methodsOMEROS CORP·Filed 2008·Granted Aug 31, 2010·16 cites·13 claims
- 0390US7550457B2Pharmaceutically effective compoundsCYTRX CORP·Filed 2007·Granted Jun 23, 2009·13 cites·19 claims
- 0489US8278327B2PDE10 inhibitors and related compositions and methodsBERGMANN JOHN E·Filed 2010·Granted Oct 2, 2012·14 cites·16 claims
- 0585US7148239B2Method of enhancing cellular production of molecular chaperon, hydroxylamine derivatives useful for enhancing the chaperon production and the preparation thereofCYTRX CORP·Filed 2003·Granted Dec 12, 2006·23 cites·34 claims
- 0684US6649628B1N-[2-hydroxy-3-(1-piperidinyl)propoxy]pyridine-1-oxide-3-carboximidoyl chloride and its use in the treatment of insulin resistanceBIOREX KUTATO FEJLESZTOE KFT·Filed 2000·Granted Nov 18, 2003·32 cites·10 claims
- 0783US7384936B2Carboxamidine derivatives and their use in the treatment of vascular diseasesCYTRX CORP·Filed 2003·Granted Jun 10, 2008·14 cites·10 claims
- 0882US7361655B2Pharmaceutically effective compoundsCYTRX CORP·Filed 2004·Granted Apr 22, 2008·13 cites·11 claims
- 0981US7126002B2Pyridine-1-oxide derivative, and process for its transformation into pharmaceutically effective compoundsCYTRX CORP·Filed 2001·Granted Oct 24, 2006·21 cites·5 claims
- 1080US7745465B2Method of enhancing cellular production of molecular chaperone, hydroxylamine derivatives useful for enhancing the chaperone production and the preparation thereofCYTRX CORP·Filed 2003·Granted Jun 29, 2010·13 cites·11 claims
- 1176US2009253690A1Pharmaceutically effective compoundsCYTRX CORP·Filed 2009·Application pending·0 cites
- 1272US6653326B1Hydroxylamine derivatives useful for enhancing the molecular chaperon production and the preparation thereofBIOREX RES & DEV CO·Filed 1996·Granted Nov 25, 2003·31 cites·31 claims
- 1372US4045433A1,3,4,5-Tetrahydro-2H-1,4-benzodiazepin-2-onesRICHTER GEDEON VEGYESZET·Filed 1975·Granted Aug 30, 1977·8 cites·2 claims
- 1450US2010267711A1Method of enhancing cellular production of molecular chaperone, hydroxylamine derivatives useful for enhancing the chaperone production and the preparation thereofCYTRX CORP·Filed 2010·Application pending·0 cites
- 1545US5919796AHydroximic acid derivatives, pharmaceutical compositions containing them, and processes for preparing the sameBIOREX KUTATO FEJLESZTOE KFT·Filed 1995·Granted Jul 6, 1999·8 cites·21 claims
- 1637US4021421ABenzodiazepine derivativesRICHTER GEDEON VEGYESZET·Filed 1975·Granted May 3, 1977·2 cites·16 claims
- 1736US6143741APharmaceutical products for curing and preventing illnesses connected with the malfunction of vascular endothelial cellsBIOREX KUTATO ES FEJLESZOERT·Filed 1997·Granted Nov 7, 2000·7 cites·15 claims
- 1836US2001051630A1Use of hydroxylamine derivatives, and method and preparations for increasing the tolerance of field crops against weather stressesFiled 2001·Application pending·0 cites
- 1930US6002002AAnti-ischaemic hydroxylamine derivatives and pharmaceutical compositionsBIOREX RESEARCH & DEV CO·Filed 1996·Granted Dec 14, 1999·2 cites·8 claims
- 2030US4371534AN4-Substituted tetrahydro-1,2,4-oxadiazin-5-one derivatives having anticonvulsive activity and pharmaceutical compositions containing themRICHTER GEDEON VEGYESZET·Filed 1981·Granted Feb 1, 1983·1 cites·5 claims
- 2129US6180787B1Process for preparing o-(3-amino-2-hydroxy-propyl)-hydroxymic acid halidesBIOREX KUTATO FEJLESZTOE KFT·Filed 1997·Granted Jan 30, 2001·0 cites·2 claims
Join the waitlist — get patent alerts
Get an alert when Laszlo Urogdi files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →